United Therapeutics Corporation $UTHR Shares Sold by Assetmark Inc.

Assetmark Inc. decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% in the 1st quarter, HoldingsChannel reports. The firm owned 616,050 shares of the biotechnology company’s stock after selling 18,906 shares during the quarter. United Therapeutics makes up 0.7% of Assetmark Inc.’s portfolio, making the stock its 28th largest holding. Assetmark Inc.’s holdings in United Therapeutics were worth $365,305,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of UTHR. Sage Rhino Capital LLC lifted its stake in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC increased its stake in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the period. Independent Advisor Alliance increased its stake in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the period. Florida Financial Advisors LLC raised its holdings in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares in the last quarter. Finally, NDVR Inc. raised its holdings in United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Royal Bank Of Canada upped their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $644.82.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $529.05 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The business’s fifty day moving average is $552.97 and its two-hundred day moving average is $530.10. The stock has a market capitalization of $22.46 billion, a P/E ratio of 19.53, a P/E/G ratio of 1.78 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $6.63 earnings per share. On average, research analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Monday, July 13th. The stock was sold at an average price of $535.99, for a total value of $5,091,905.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $21,714,562.87. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director directly owned 450 shares in the company, valued at $247,765.50. This represents a 41.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 564,743 shares of company stock valued at $316,423,257 over the last three months. Insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.